Plasma estrone and estrone sulphate in breast cancer patients treated with the aromatase inhibitor CGS 16949A.
Klepp
R
R
Department of Oncology, University of Trondheim, Norway.
Lønning
P E
PE
Kvinnsland
S
S
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy; D004970:Estrone / Q000031:analogs & derivatives* / Q000097:blood*; D017316:Fadrozole; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use*; D013997:Time Factors
D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D007093:Imidazoles; D009570:Nitriles; D004970:Estrone; D017316:Fadrozole; C017296:estrone sulfate